locus is regulated by these mechanisms, we searched for and found two transcripts, p21B and p21C, that are expressed from an alternate promoter in the ®rst intron of the p21 gene. While p21C encodes the p21 cyclin-dependent kinase inhibitor, p21B encodes a novel protein and the transcript is ubiquitously expressed in 16 human tissues tested. Like p21, both p21B and p21C are induced by DNA damage, p53, and other p53 family members through a proximal p53 response element in the promoter of p21B and p21C. However, unlike p21, which induces cell cycle arrest, we found that overexpression of p21B induces apoptosis. These ®ndings indicate that the p21 locus expresses at least two structurally distinct, but functionally related, variants of the p21 gene from discrete promoters. Oncogene (2002) 21, 1285 ± 1294. DOI: 10.1038/sj/ onc/1205191
Keywords: p53; p21; p218; apoptosis Mutations in the p53 tumor suppressor gene are the most frequently occurring genetic lesions in human cancers. p53, a sequence-speci®c DNA-binding protein, can be activated by cellular insults such as DNA damage, oncogene activation, hypoxia, and nucleotide deprivation (Agarwal et al., 1998; Evan and Vousden, 2001; Giaccia and Kastan, 1998; Ko and Prives, 1996; Vogelstein et al., 2000) . The activated p53 protein induces a number of target genes that mediate cell cycle arrest or apoptosis (Chen, 1999; el-Deiry, 1998; Evan and Vousden, 2001) . p21 Waf1/Cip1 is a well-characterized p53 target and can mediate p53-dependent cell cycle arrest (el-Deiry et al., 1993; Harper et al., 1993; Xiong et al., 1993) . p21 belongs to the Cip/Kip family of cyclin dependent kinase (CDK) inhibitors (CKIs), which includes p21, p27 KIP1 , and p57
KIP2
. Members of the Cip/Kip family share a conserved domain at their amino termini that inhibits the activity of CDKs (Nakayama, 1998) . Another family of CKIs is the INK4 family, which includes p16 INK4A , p15 INK4B , p18 INK4C , and p19 INK4D . Members of the INK4 family possess four tandem ankyrin repeat motifs and preferentially inhibit the activity of CDK4 or CDK6 (Sherr and Roberts, 1999) . Among these CKIs, alternative splicing and expression from an alternate promoter have been shown to regulate gene expression for the p15 INK4B , p16 INK4A , and p57 KIP2 loci (Duro et al., 1995; Mao et al., 1995; Quelle et al., 1995; Stone et al., 1995; Tokino et al., 1996; Tsubari et al., 1997) . To determine whether these mechanisms regulate the p21 locus, we screened a cDNA library made from the mRNA of induced p53-7 cells, which are SAOS2 cells that inducibly express p53 under the control of a tetracycline-regulated promoter (Chen et al., 1996) . Using a probe corresponding to the p21 gene, we identi®ed several p21 cDNAs and one novel cDNA. The novel cDNA, designated p21B, consists of two exons with a total of 4180 nucleotides (Figure 1a) . The ®rst exon, exon IB (111 nucleotides in size), is located downstream of the p21 exon I at nucleotides 3370 to 3481 and it is spliced to exon IIB (4067 nucleotides in size), which starts at nucleotide 4555 ( Figure 1a ). The p21B transcript contains an ORF that encodes a protein of 123 amino acids ( Figure 1b ) and shows no homology to any known proteins in GenBank.
In an alternative approach, we performed RT ± PCR using primers Exon IB-F and Exon II-R (Figure 1a) . Total RNA was puri®ed from p53-7 cells that were induced to express wild type p53, or MCF7 breast carcinoma cells that were treated with the DNA damaging agent camptothecin to induce endogenous wild type p53. In this manner, we identi®ed p21C, which consists of an extended form of the p21B exon I (exon IC, 652 nucleotides in size) (Figure 1a ). Exon IC is spliced to the p21 exons II and III. Although exon IC of p21C is much larger than exon I of p21, the ORF in the p21C transcript is identical to that in p21, and hence we believe it also encodes the p21 protein ( Figure 1a) .
To con®rm that the p21B transcript was not an artifact of tumor cells, we analysed the expression pattern of p21B in cDNA samples from 16 normal human tissues (ClonTech, Palo Alto, CA, USA). These cDNAs were subjected to PCR ampli®cation using primers speci®c for p21B (Exon IB-F and Exon IIB-R), p21 (Exon I-F and Exon III-R) (Figure 1a) , and GAPDH. We found that both p21B and p21 were ubiquitously expressed in all human tissues tested Figure 1 Three RNA transcripts are expressed from the p21 locus. (a) Representation of the p21 locus and location of primers used to detect p21, p21B, and p21C. The position of the ®rst nucleotide of the p21 transcript (GenBank Accession # Z85996) in the genomic DNA is assigned as the start site of the p21 locus. The transcript for p21 is produced by splicing exons I, II and III to yield a 2.1 kilobase (kb) mRNA with an ORF (vertical stripes) that encodes the 164 amino acid p21 protein. An alternative ®rst exon, exon IB, is spliced to exon IIB, yielding a 4.1 kb transcript with an ORF (horizontal stripes) that encodes the 123 amino acid p21B protein. The transcript for p21C is produced by splicing exon IC, II and III. This yields a 2.7 kb mRNA with an ORF identical to that in the p21 transcript. Exon IB-F and Exon IIB-R primers were used to detect a 338-bp fragment of p21B. Exon IB-F and Exon II-R primers were used to detect a 1267-bp fragment of p21B and 975-bp fragment of p21C. Exon I-F and Exon III-R primers were used to detect a 837-bp fragment of p21. (b) Amino acid sequence of p21B. (c) PCR ampli®cation of p21B, p21 and GAPDH cDNAs from 16 human tissues. The primers used to amplify GAPDH were: forward primer 5'-TGA AGG TCG GAG TCA ACG GAT TTG GT-3', and reverse primer 5'-CAT GTG GGC CAT GAG GTC CCC AC-3'. The primers used to amplify p21 were: forward primer (Exon I-F) 5'-AGG CAC CGA GGC ACT CAG AG-3', and reverse primer (Exon III-R) 5'-AAG CCG GCC CAC CCA ACC TC-3'. The primers used to amplify p21B were: forward primer (Exon IB-F) 5'-GTG GGG TTC AAT ACT ACA GCA CAG-3', and reverse primer (Exon IIB-R) 5'-TGG TCC TAG CTC TGC CAG TTA CTA C-3'. The cycles used to detect GAPDH, p21, and p21B were 25, 30 and 35, respectively. Ampli®ed cDNAs were separated by 1% agarose gel and visualized by ethidium bromide staining p21B, a variant of p21 Waf1/Cip1 , is induced by the p53 family S Nozell and X Chen ( Figure 1c , upper and middle panels). To con®rm the identity of the PCR products, we cloned and sequenced the ampli®ed p21B and p21 cDNAs from spleen, testis, lung, and pancreas, and found that they were derived from the p21B and p21 transcripts, respectively. Typically, 30 PCR cycles were needed to detect p21 while 35 PCR cycles were needed to detect p21B. These data suggest that in a normal cell, p21B is expressed less abundantly than p21. In response to cellular stresses such as DNA damage, p53 is activated and induces p21 expression. To determine whether p21B and p21C are also induced by DNA damage, we performed semi-quantitative RT ± PCR analysis. The primers used to detect p21B, both p21B and p21C, and p21 are shown in Figure 1a . Total RNA was isolated from MCF7 cells that were untreated or treated with camptothecin. Camptothecin is a topoisomerase I inhibitor that can induce double strand DNA breaks (Nelson and Kastan, 1994) . We found that both p21B and p21C, like p21, were induced in MCF7 cells that express wild type p53 following DNA damage ( Figure 2a ). As before, p21 could be detected in fewer PCR cycles than p21B, suggesting that p21B is less abundantly expressed than p21 in both normal and cancerous human tissue samples.
To further con®rm these results, we performed Northern blot analyses using poly(A) + RNA puri®ed from MCF7, HCT116, and HCT116 p537/7 cells that were untreated or treated with 300 nM camptothecin or 0.5 mg/ml doxorubicin. Doxorubicin is a topoisomerase II inhibitor that can induce double strand DNA breaks (Nelson and Kastan, 1994) . HCT116 cells harbor two wild type p53 alleles whereas in HCT116 p537/7 cells, both p53 alleles have been deleted by somatic gene targeting (Bunz et al., 1998) . We found that p21B, like p21, was induced in MCF7 and HCT116 cells but not in HCT116 p537/7 cells following DNA damage (Figure 2b ). These results suggest that the DNA damage induction of p21B is p53-dependent. Since p21B is transcribed from the p21 locus, we wanted to analyse the expression of p21B in p21-null 8OS14 cell line (Waldman et al., 1995) . 8OS14 is an HCT116 derivative in which the p21 coding region was substituted with the neomycin gene in one allele and with the hygromycin gene in the other allele using somatic gene targeting ( (Waldman et al., 1995) ; Figure 2c ). Total RNA was puri®ed from 8OS14 cells that were untreated or treated with 300 nM camptothecin. Semi-quantitative RT ± PCR was performed with primers Exon IB-F and Exon IIB-R to detect p21B, and primers Exon 1-F and Neo to detect the p21-neomycin transcript (Figure 2c ). We found that p21-neomycin was induced by DNA damage (Figure 2d ), suggesting that the p21 promoter is still responsive to DNA damage in p21-null 8OS14 cells. Furthermore, we found that p21B, like p21-neomycin, was also induced by DNA damage (Figure 2d) .
Recently, we and others have shown that p73, a structural and functional homolog of p53, can regulate some p53 target genes (Di Como et al., 1999; Jost et al., 1997; Yu et al., 1999; Zhu et al., 1998) . To determine whether p73 can regulate p21B, we examined the expression of p21B in M7-p73b-38 cells that were uninduced or induced to express p73b. We found that p21B, like p21, is induced by p73b (Figure 2e ). These results suggest that p21B is regulated by both p53 and p73.
Previous studies have shown that the p21 locus contains two p53 response elements located upstream of the p21 promoter at nucleotides 75669 and 74783, respectively ( Figure 3a ) (el-Deiry et al., 1992; Funk et al., 1992) . While it is possible that these may regulate p21B and p21C, we wanted to determine whether p21B and p21C are regulated by a more proximal p53 response element in their own promoter. We searched for such an element in the genomic DNA sequence that contains the p21 locus (GenBank Accession #Z85996), and found a potential p53 response element located upstream of the p21B and p21C transcription start site at nucleotide 7138 ( Figure 3a ). This sequence, CAGCTAGTTG ccc AGGCTAGTCT, contains two mismatches (in bold italics) in the non-critical positions of the p53-binding site (el-Deiry et al., 1992; Funk et al., 1992) . It should be mentioned that the two previously identi®ed p53 response elements also contain two mismatches (in bold italics; Figure 3a ) in both critical and non-critical positions of the p53-binding site.
To determine whether this binding site in the p21B and p21C promoter is responsive to p53, we cloned a 432-base pair (bp) fragment from 7272 to +160, which contains the potential p53 response element and a TATA box, upstream of a promoterless luciferase reporter construct, and the resulting plasmid was designated pGL2/wt (Figure 3a) . Similarly, we cloned a 258-bp fragment from 798 to +160, which contains the TATA box but not the potential p53 response element, upstream of a promoterless luciferase construct, and the resulting plasmid was designated pGL2/ (798) (Figure 3a) . Each of the reporter vectors was cotransfected into H1299 cells with either a pCMV control vector, or a pCMV vector that expresses either wild type p53 or mutant p53(R175H). The renilla luciferase assay vector pRL-CMV was also cotransfected as an internal control. We found that the luciferase activity for pGL2/wt was increased approximately ®vefold by wild type p53, but not by mutant p53 (Figure 3b ). However, neither wild type p53 nor mutant p53(R175H) was capable of signi®cantly increasing the luciferase activity for pGL2/(798) (Figure 3b ). These results suggest that the potential p53-binding site in the p21B and p21C promoter is responsive to p53.
To further con®rm that the potential p53-binding site in the p21B and p21C promoter is responsive to p53, we cloned a 276-bp fragment from 7116 to +160 upstream of a promoterless luciferase reporter construct, and the resulting plasmid was designated pGL2/ (7116) (Figure 3a ). This fragment contains the TATA box and promoter region up to but not including the putative p53 response element. Similarly, we generated Oncogene p21B, a variant of p21 Waf1/Cip1 , is induced by the p53 family S Nozell and X Chen
Figure 2 p21B and p21C are induced by DNA damage, p53, and p73. (a) p21B and p21C are induced by DNA damage. RT ± PCR ampli®cation of p21, p21B, and p21C transcripts in MCF7 cells that were untreated (7) or treated (+) with 300 nM camptothecin (CPT) for 24 h. First strand cDNA was synthesized with Superscript reverse transcriptase (Life Technologies, Grand Island, NY, USA) according to the manufacturer's instructions. Linear PCR ampli®cation was established by controlling the concentration of template and number of cycles. Sample input was normalized to the housekeeping gene GAPDH. The primers used to detect p21B, and p21 are shown in Figure 1a . The primers used to amplify p21B and p21C were: forward primer (Exon IB-F) and reverse primer (Exon II-R) 5'-TGA CAG GTC CAC ATG GTC TTC C-3'. A control PCR reaction was performed with cDNA template synthesized without reverse transcriptase (-RT). The cycles used to amplify p21B, both p21B and p21C, p21, and GAPDH were 35, 35, 30, and 25, respectively. (b) p21B and p21 are induced by DNA damage in cells that express wild type p53 but not in cells that are p53-null. Northern blots were prepared using 4 mg poly(A) + RNA puri®ed from MCF7, HCT116, and HCT116 p537/7 cells, which were untreated or treated with 300 nM camptothecin or 0.5 mg/ml doxorubicin for 24 h. The probe cDNAs for p21, p21B, and GAPDH were PCR-ampli®ed from human spleen cDNAs (ClonTech, Palo Alto, CA, USA) and con®rmed by sequencing to be derived from the p21, p21B, and GAPDH genes. The blots were probed with p21B and then reprobed with p21 and GAPDH, respectively. Northern blots for p21B were exposed to ®lm for 4 days, while Northern blots for p21 and GAPDH were exposed to ®lm for 2 days. The fold increase of p21B and p21 over the control as normalized to GAPDH is shown below the blot. (c) Representation of the p21 locus in p21-null 8OS14 cells and the location of primers used to detect p21B and p21-neomycin. The p21 ORF is substituted with the neomycin gene in one allele and with the hygromycin gene in other allele (Waldman et al., 1995) . (d) p21-neomycin and p21B are induced by DNA damage in p21-null 8OS14 cells. Total RNA was puri®ed from 8OS14 cells that were p21B, a variant of p21 Waf1/Cip1 , is induced by the p53 family S Nozell and X Chen a 432-bp fragment from 7272 to +160 with mutations in the critical residues of the p53 response element. This was cloned upstream of a promoterless luciferase reporter construct and the resulting plasmid was designated pGL2/mutant (Figure 3a) . The pGL2/ mutant reporter construct is identical to pGL2/wt in size and composition, except there are two point mutations in both half sites of the p53 response element in the pGL2/mutant construct (G?A, C?T). Each of the reporter constructs, pGL2/wt, pGL2/(7116) or pGL2/mutant, were co-transfected into H1299 cells with either a pCMV control vector, or a pCMV vector that expresses either wild type p53 or mutant p53(R175H). The renilla luciferase assay vector pRL-CMV was also co-transfected as an internal control. We found that neither wild type p53 nor mutant p53(R175H) was capable of signi®cantly increasing the luciferase activity for pGL2/(7116) or pGL2/mutant (Figure 3c ). These results indicate that the potential p53-binding site in the p21B and p21C promoter is indeed responsive to p53. p73 and p63, two p53-related proteins, are similar to p53, especially in their DNA binding domains (Chen, 1999; Kaelin, 1999; Yang and McKeon, 2000) . Both genes also undergo extensive splicing and both proteins have been shown to induce numerous p53 targets (Di Como et al., 1999; Jost et al., 1997; Kaghad et al., 1997; Yang et al., 1998; Yu et al., 1999; Zhu et al., 1998) . To determine whether p73 and p63 can also regulate the p21B/p21C promoter through this newly identi®ed response element, pGL2/wt or pGL2/(798) was cotransfected into H1299 cells with a pcDNA3 control vector, or a pcDNA3 vector that expresses either p73b, mutant p73b292, p63a, or p63g. We found that the luciferase activity for pGL2/wt was signi®cantly increased by p73b (20-fold) and p63g (13-fold), but not by p73b292 and p63a (Figure 3b ). In contrast, none of these p63 and p73 isoforms increased the luciferase activity for pGL2/(798) (Figure 3b ). These results are consistent with previous reports demonstrating that p73b and p63g, but not p73b292 and p63a, are capable of regulating several p53 targets (Di Como et al., 1999; Yang et al., 1998; Yu et al., 1999; Zhu et al., 1998) .
To analyse whether p53 binds directly to this putative p53 response element, a 47-bp DNA fragment spanning the p53 response element (5'-TCG AGG GTC TCA GCT AGT TGC CCA GGC TAG TCT TGG ACC-3') was synthesized, 32 P-labeled, and analysed in an electrophoretic mobility shift assay (EMSA). We found that when the puri®ed p53 protein was mixed with the DNA fragment, a complex was detected, presumably containing both p53 and the 32 P-labeled DNA, that was not detected in the absence of p53 protein (Figure 3d , compare lanes 1 and 2). Upon addition of the anti-p53 monoclonal antibody PAb1801 to the mixture of p53 and DNA, the complex was`supershifted' (Figure 3d,  lane 3) . Interestingly, the supershifted band (DNA+p53+1801) was signi®cantly more noticeable than the shifted band (DNA+p53) (Figure 3d, compare  lanes 2 and 3) . This is consistent with previous data wherein the addition of N-terminal speci®c antibodies against p53, such as PAb1801, decreased the rate of dissociation between DNA and p53 and enabled more DNA to remain bound to p53 (Cain et al., 2000) . To demonstrate that this binding was sequence-speci®c, an excess amount of an unlabeled p53-binding site from the ribosomal gene cluster (RGC) was used as a competitor (Kern et al., 1991) . The unlabeled RGC competed with the 32 P-labeled 47-bp DNA fragment and inhibited the formation of the p53-DNA complex in a dose dependent manner (Figure 3d , lanes 4 ± 6). We also tested whether a 47-bp DNA fragment containing a mutant p53-binding site (5'-TCG AGG GTC TCA GAT ATT TGC CCA GGT TAA TCT TGG ACC-3') could compete with the 32 P-labeled DNA fragment in a dose-dependent manner. We found that the unlabeled DNA fragment containing the mutant p53-binding site was unable to compete with the 32 P-labeled 47-bp DNA fragment and to inhibit the formation of the p53-DNA complex (data not shown). These results indicate that p53 speci®cally interacts with the putative p53-responsive element present in the p21B and p21C promoter.
Activation of p53 typically results in at least two well-characterized cellular responses, cell cycle arrest and apoptosis. Because p53 is capable of inducing p21B, we wanted to determine whether expression of p21B contributes to cell cycle regulation. To do this, we established several stable MCF-7 cell lines that inducibly express hemagluttinin-tagged p21B (HAp21B) under the control of a tetracycline-regulated promoter. A representative clone, MCF-7-A, was used to measure the rate of cell growth in the absence and presence of p21B protein (Figure 4a ). Growth rate analyses showed that the growth of MCF-7-A was inhibited when p21B was expressed (data not shown).
The negative eect of p21B on cell growth may be indicative of either cell cycle arrest or apoptosis. To distinguish between these two events, we performed DNA histogram analysis. We found that MCF-7-A cells grown in the absence of p21B protein displayed a normal cell cycle DNA pro®le (Figure 4b ). However, in the presence of p21B, the number of cells that exhibited a sub-G1 DNA content increased from 7 to 15% (compare Figure 4b and c) , suggesting that p21B induces apoptosis. untreated or treated with 300 nM camptothecin for 24 h, and semi-quantitative RT ± PCR was performed as described previously. The primers used to amplify p21-neomycin in 8OS14 cells were: forward primer (Exon 1-F) and reverse primer (Neo) 5'-GAT GTT TCG CTT GGT GGT CG-3'. The cycles used to amplify p21B and p21-neomycin (p21-neo) were 35 and 28, respectively. (e) p21B is induced by p73b. Northern blots were prepared using 5 mg poly(A) + RNA puri®ed from M7-p75b-38 cells that were uninduced (7) or induced (+) to express p73b as described previously. Northern blots for p21B were exposed to ®lm for 2 days, while Northern blots for p21 and GAPDH were exposed to ®lm for 24 h Oncogene p21B, a variant of p21 Waf1/Cip1 , is induced by the p53 family S Nozell and X Chen
To examine this further, we performed four additional assays to detect other features of apoptosis. First we measured apoptosis by an annexin V/ propidium iodide staining assay. We found that in the absence of p21B expression, 7% of MCF-7-A cells (sum of the upper and lower right quadrants) were annexin V positive (Figure 4d ). However, upon p21B expression, the percentage of annexin V positive cells increased from 7 to 22% (compare Figure 4d and e) . Next, we performed Trypan blue dye exclusion assays. In the absence of p21B protein, the number of apoptotic cells was 7% (Figure 4f ). However, in the presence of p21B, the number of cells undergoing apoptosis increased to 13% (Figure 4f) .
Apoptosis can be initiated through either the death receptor pathway or the mitochondrial pathway. The latter pathway involves stimuli that induce the release of cytochrome c from the mitochondria and the dissolution of mitochondrial membrane integrity (Green and Reed, 1998) . To determine whether p21B expression can alter mitochondrial membrane integrity, we stained cells with Mitosensor, a mitochondrialspeci®c cationic dye (ClonTech, Palo Alto, CA, USA). In healthy cells, the Mitosensor dye aggregates inside the mitochondria and¯uoresces red, which can be measured by¯uorescence-activated cell sorting (FACS). However, in apoptotic cells, the mitochondrial membrane is disrupted such that the Mitosensor dye cannot aggregate, and hence there is a reduction in the relative mean¯uorescence. As a positive control, we analysed cells that inducibly express p53. Previous studies have shown that p53 promotes the release of cytochrome c and disrupts mitochondrial membrane integrity (Schuler et al., 2000) . We found that upon p53 p21B, a variant of p21 Waf1/Cip1 , is induced by the p53 family S Nozell and X Chen or p21B expression, the relative mean¯uorescence decreased (Figure 4g ), suggesting that p21B may induce apoptosis via the mitochondrial pathway. We also analysed the nuclear morphology of cells that inducibly expressed either HA-p53 or HA-p21B under the control of a tetracycline-regulated promoter. MCF7 cells that inducibly expressed either HA-p53 or HA-p21B were analysed by indirect immuno¯uores-cence and cell nuclei were counterstained with the DNA speci®c dye DAPI. Using this technique, we noted that many cells that expressed p53 (Figure 4h ± j) or p21B (Figure 4k ± m) also exhibited DNA condensation, a characteristic hallmark of apoptosis. To determine if there was a correlation between chromatin condensation and p53 or p21B expression, we counted the number of cells that expressed either p53 or p21B, and which also exhibited condensed chromatin. As a negative control, we analysed the nuclei of MCF7 cells in the absence of either p53 or p21B expression, and found that approximately 5% of control cells exhibited condensed chromatin (Figure 4n ). In contrast, we found that 31.1+1% and 18.0+2% of cells that expressed p53 and p21B, respectively, exhibited condensed nuclei (Figure 4h ). These data suggest that p21B, like p53, is capable of inducing apoptosis.
In this study, we have identi®ed two novel transcripts of the p21 gene, p21B and p21C, both of which appear to be expressed from an alternate promoter in the p21 locus. p21B contains two unique exons and encodes a protein that is not homologous to The potential p53-binding site in the p21B and p21C promoter is responsive to p53, p73b, and p63g, but not to p53(R175H), p73b292, and p63a. One mg of either pGL2/wt or pGL2/(798) was co-transfected into H1299 cells with 1.0 mg of pCMV control vector or a pCMV vector that expresses wild type p53 or mutant p53(R175H). To determine whether the potential p53-binding site is responsive to p73 and p63, 1.0 mg of each construct was co-transfected into H1299 cells with 1.0 mg of pcDNA3 control vector or a pcDNA3 vector that expresses p73b, p73b292, p63a, or p63g. Fifty ng of renilla luciferase assay vector pRL-CMV (Promega, Madison, WI, USA) were also co-transfected as an internal control. Dual luciferase assay was performed in triplicate according to the manufacturer's instructions (Promega, Madison, WI, USA). The fold increase in relative luciferase activity is a product of the luciferase activity induced by p53, p53(R175H), p73b, p73b292, p63a, or p63g divided by that induced by an empty pCMV vector. (c) The potential p53 binding in the p21B/p21C promoter is necessary for p53 induction. One mg of either pGL2/wt, pGL2/(7116), or pGL2/mutant was co-transfected into H1299 cells with 1.0 mg of pCMV control vector or a pCMV vector that expresses wild type p53 or mutant p53 (R175H). Dual luciferase was performed as previously described and the fold increase in relative luciferase activity was determined similarly to that in (b). (d) p53 binds to the putative p53-response element. EMSA analysis was performed with a 47 bp DNA fragment spanning the potential p53 response element in the p21B and p21C promoter as previously described (Zhu et al., 1999) Oncogene p21B, a variant of p21 Waf1/Cip1 , is induced by the p53 family S Nozell and X Chen Figure 4 Overexpression of p21B inhibits cell growth and induces apoptosis. (a) Generation of a stable MCF-7 cell line, MCF-7-A, that inducibly expresses p21B under the control of a tetracycline-regulated promoter. Levels of p21B and actin were assayed by Western blot analysis. The blots were probed with the mouse monoclonal anti-HA antibody 12CA5 (upper panel) and anti-actin antibody (lower panel), respectively. (b,c) DNA content was quanti®ed by propidium iodide staining of ®xed MCF-7-A cells in the absence or presence of p21B as previously described (Dohn et al., 2001) . (d,e) Apoptotic cells were quanti®ed by propidium iodideannexin V staining of MCF-7-A cells that were grown in the absence or presence of p21B for 3 days as previously described (Dohn et al., 2001) . (f) Apoptotic MCF-7-A cells were measured by Trypan blue exclusion assay in the absence or presence of p21B for 3 days as previously described (Dohn et al., 2001) . (g) The mitochondrial membrane integrity was assayed in MCF-7-A and M7-p53-24 cells that were uninduced or induced to express p21B and p53, respectively, as previously described . (h ± m) Expression of p53 or p21B induces chromatin condensation. MCF7 cells that inducibly express HA-tagged p53 or HA-tagged p21B under a tetracycline-regulated promoter were generated as previously described . Cells were seeded on 8-well chamber slides, washed with PBS, ®xed with 10% formalin, and permeabilized with 1% NP-40. The cells were then blocked with 15% goat serum and incubated with rabbit anti-HA antibody (Sigma, St. Louis, MO, USA), followed by Texas Red-conjugated goat anti-rabbit (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA) for 60 min at room temperature. Nuclei were visualized by labeling with 4',6-diamidino-2-phenylindole (DAPI) (Molecular Probes, Inc., Eugene, OR, USA). For all experiments, coverslips were mounted with Prolong (Molecular Probes, Inc., Eugene, OR, USA), and the stained cells were analysed by¯uorescent microscopy. ARF function in dierent pathways, each contributes to cell cycle regulation and both can act as a cell cycle checkpoint. This type of redundancy may be critical to maintaining cell cycle control in response to a wide array of cellular or environmental stresses. For example, oncogenic Ras induces the upregulation of both p16
INK4A and p14 ARF (Palmero et al., 1998; Serrano, 1997) . However, loss of pRB activity induces p16
INK4A whereas DNA damage and BRCA1 induce p14 ARF (Benedict et al., 1999; Somasundaram et al., 1999) .
This explanation might also be applied to the p21 locus. p21 is capable of inducing cell cycle arrest in response to various cellular stresses and also plays an important role in the process of cellular dierentiation and senescence (el-Deiry, 1998; Ko and Prives, 1996; Vogelstein et al., 2000) . Here, we have found that p21B may also be involved in cell cycle regulation. The promoters for p21 and p21B/p21C contain many common putative response elements for transcription factors known to induce p21, including p53, E2F, C/ EBPb, STAT1, STAT3, and AP2 (Gartel and Tyner, 1999) . Therefore, in response to certain stimuli such as DNA damage, p21 and p21B can be expressed simultaneously from both promoters. The p21 promoter also contains response elements for STAT5, BRCA1, SMAD3, and SMAD4, which are also known to induce p21 (Gartel and Tyner, 1999) . However, these response elements appear to be absent from the p21B/p21C promoter. Similarly, there are several potential response elements for NF-kB and the serum response factor in the p21B/p21C promoter that are not present in the p21 promoter (data not shown). Therefore, it is possible that in response to a particular stimulus, p21, but not p21B, is induced, and vice versa.
Of all the activities identi®ed for p53, perhaps the best characterized are cell cycle arrest and apoptosis. However, it is still uncertain what molecular cues signal p53 to induce apoptosis as opposed to cell cycle arrest. Interestingly, we found that a single locus, p21, can express two unique gene products, both of which appear to have a role in cell cycle regulation. Therefore, future studies to determine how p53 family members and various stress signals dierentially regulate p21 and p21B may provide some insight about how a cell chooses to undergo cell cycle arrest and/or apoptosis.
